ReviewDisease markers2022
Interplay between Dysbiosis of Gut Microbiome, Lipid Metabolism, and Tumorigenesis: Can Gut Dysbiosis Stand as a Prognostic Marker in Cancer?
Review in Disease markers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 3 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- The Clinical Impact of Time-restricted Eating on Cancer: A Systematic Review.Nutrition reviews · 2025Pooled it
- Diabetes Driven Oncogenesis and Anticancer Potential of Repurposed Antidiabetic Drug: A Systemic Review.Cell biochemistry and biophysics · 2024Pooled it
- Intratumoral and fecal microbiota reveals microbial markers associated with gastric carcinogenesis.Frontiers in cellular and infection microbiology · 2024Pooled it
- Review
- Serum Trimethylamine-International journal of molecular sciences · 2026Article
- Reprogramming the gastrointestinal microenvironment with intelligent biomaterials and digital medicine: a perspective on precision intervention for digestive diseases.Frontiers in bioengineering and biotechnology · 2026Article
- Microbiota and lipid mediators: from molecular crosstalk to therapeutic opportunities.Frontiers in pharmacology · 2026Review
- Polysaccharides-gut microbiota interaction: mechanisms regulating the hepatocellular carcinoma immune microenvironment.Frontiers in immunology · 2026Review
- Gastric microbiota-specific signatures in adults with obesity and Helicobacter pylori-negative gastritis.European journal of clinical investigation · 2025Article
- Gut microbiome and nutritional strategies in gastrointestinal cancers: Clinical implications and therapeutic perspectives.World journal of clinical oncology · 2025Review
- Unveiling gut microbiome divergence in sellar-parasellar masses and brain tumors: A link beyond the skull.Neurosurgical review · 2025Article
- Untargeted metabolomics analysis of serum metabolic signatures as novel biomarkers for gastric carcinoma.World journal of clinical oncology · 2025Article
- Gastric Cancer and Microbiota: Exploring the Microbiome's Role in Carcinogenesis and Treatment Strategies.Life (Basel, Switzerland) · 2025Review
- Risk factors and outcomes of Clostridioides difficile infection in patients with colorectal cancer: critical perspective in management.Gut pathogens · 2025Review
- Review of the mechanisms of the biliary-enteric axis in the development of cholangiocarcinoma.World journal of clinical oncology · 2025Review
- The coadministration of Lactobacillus probiotic augments the antitumor effect of telmisartan in rats.AMB Express · 2025Article
- The Potential Role of Intestinal Microbiota on the Intestine-Protective and Lipid-Lowering Effects of Berberine in Zebrafish (Metabolites · 2025Article
- Exploring the Mechanisms of Gastroesophageal Reflux Disease Based on the Brain-Gut Axis Theory.International journal of general medicine · 2025Review
- From gut to proteomics: the impact ofFrontiers in oncology · 2025Article
- Microbial and Metabolic Gut Profiling across Seven Malignancies Identifies FecalInternational journal of molecular sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gut bacterial community is involved in the metabolism of bile acids and short-chain fatty acids (SCFAs). Bile acids are involved in the absorption of fat and the regulation of lipid homeostasis through emulsification and are transformed into unconjugated bile acids by the gut microbiota. The gut microbiota is actively involved in the production of bile acid metabolites, such as deoxycholic acid, lithocholic acid, choline, and SCFAs such as acetate, butyrate, and propionate. Metabolites derived from the gut microbiota or modified gut microbiota metabolites contribute significantly to host pathophysiology. Gut bacterial metabolites, such as deoxycholic acid, contribute to the development of hepatocellular carcinoma and colon cancer by factors such as inflammation and oxidative DNA damage. Butyrate, which is derived from gut bacteria such as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.